#USA #Radnor #Algeness® #Advanced Aesthetic Technologies #Lanzhou Biotech

Advanced Aesthetic Technologies Announces Approval of Algeness® VL Agarose Facial Injection Filler in China

Advanced Aesthetic Technologies, Inc. (AAT) has achieved a significant milestone by securing approval for the marketing of Algeness® VL agarose facial injection filler in China. This innovative dermal filler became officially registered as a Class III medical device, marking a pivotal moment for aesthetic treatments in the region. The approval comes through the efforts of AAT's development and distribution partner, Lanzhou Biotechnique Development Co., Ltd. (LanDev), part of the China National Biotec Group Company Limited.

Algeness® VL is notable for being the first agarose-based injection filler approved in China, offering a 2.5% concentration of a unique agarose gel formulation. This product represents the culmination of extensive scientific research aimed at providing effective solutions for facial volume loss and wrinkles. The pioneering work of AAT’s team of scientists and physicians has led to the creation of a fully natural and biodegradable injectable implant designed for optimal safety and efficacy.

Doug Abel, the President and CEO of AAT, expressed enthusiasm about launching Algeness® into China’s vast aesthetic market. According to Abel, “We are excited and look forward to the entry of Algeness® into the large aesthetic market in China through our partner LanDev. This approval marks a significant accomplishment involving our teams and regulatory advisors.” LanDev’s prestigious background as a domestic manufacturer of botulinum toxin significantly boosts the potential success of Algeness® in a competitive market.

This achievement comes after several key developments over the past two years for AAT, including successful advancement through clinical trials aimed at U.S. FDA approval, acquiring a CE Mark under stringent regulations, and gaining controlling interest in Ghimas, S.p.A., the original developer of Algeness®. These milestones illustrate AAT's dedication to expanding its global reach and product offerings.

The approval of Algeness® in China heralds a transformative era for AAT, providing a substantial opportunity to demonstrate the clinical effectiveness of this unique product. Dr. Omer Buhsem, a prominent plastic surgeon and Medical Director for Algeness®, remarked on the product’s revolutionary design and its potential to deliver safe and effective aesthetic results. Meanwhile, dermatologists such as Dr. Tatjana Pavicic praised Algeness® for its natural composition and exceptional outcomes over nearly a decade of use.

Overall, the entry of Algeness® VL into China, combined with the strategic partnership with LanDev, sets the stage for AAT to further define its role within the aesthetic medicine market. The product's favorable reviews from leading aesthetic practitioners worldwide affirm its designed purpose and effectiveness, promising a bright future for both AAT and the Algeness® brand.

As AAT continues to pursue U.S. registration and expand its market presence, the company stands at the forefront of innovation in the aesthetic medicine landscape with Algeness® leading the way.